CytoDyn director Scott Kelly resigns; Stephen Simes appointed to board.

CytoDyn Inc.

Scott Kelly resigned as director effective Oct 13, 2022; remains CMO and Head of Business Development.
Stephen Simes appointed director same day, filling Kelly's vacancy.
Simes has 40+ years pharma experience, former CEO of BioSante and RestorGenex, director at several firms.
Simes compensated per nonemployee director policies with cash retainers and stock options.
No disclosable transactions or family relationships between Simes and other officers/directors.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Stephen M. Simes

Director

CYDY · CytoDyn Inc.

Effective: 2022-10-13
Filed: October 19, 2022, 7:59 PM ET

On October 13, 2022, the Company’s Board of Directors (the “Board”) approved the appointment of Stephen M. Simes (“Mr. Simes”) as a director of the Company, effective October 13, 2022.

Departed

Scott A. Kelly

Director

CYDY · CytoDyn Inc.

Effective: 2022-10-13
Successor: Stephen M. Simes
Filed: October 19, 2022, 7:59 PM ET

On October 13, 2022, Scott A. Kelly, M.D. (“Dr. Kelly”) provided written notice to the Board Chair of CytoDyn Inc. (the “Company”) of his resignation as a director of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen M. Simes was appointed as Director at CytoDyn Inc..

Action: appointed
Role: Director

Exact text from the filing

On October 13, 2022, the Company’s Board of Directors (the “Board”) approved the appointment of Stephen M. Simes (“Mr. Simes”) as a director of the Company, effective October 13, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott A. Kelly resigned as Director at CytoDyn Inc..

Action: resigned
Role: Director

Exact text from the filing

On October 13, 2022, Scott A. Kelly, M.D. (“Dr. Kelly”) provided written notice to the Board Chair of CytoDyn Inc. (the “Company”) of his resignation as a director of the Company, effective immediately.

View on SEC.gov

CytoDyn Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-015082

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.